NUVL - Nuvalent - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

NUVL is currently covered by 5 analysts with an average price target of $98.1. This is a potential upside of $24.86 (33.94%) from yesterday's end of day stock price of $73.24.

Nuvalent's activity chart (see below) currently has 8 price targets and 27 ratings on display. The stock rating distribution of NUVL is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 61.75% with an average time for these price targets to be met of 129.67 days.

Highest price target for NUVL is $135, Lowest price target is $115, average price target is $127.8.

Most recent stock forecast was given by SWAYAMPAKULA RAMAKANTH from HC WAINWRIGHT on 24-Jun-2025. First documented stock forecast 23-Aug-2021.

Currently out of the existing stock ratings of NUVL, 21 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$130

$53.96 (70.96%)

$110

1 months 27 days ago
(24-Jun-2025)

0/4 (0%)

$53.12 (69.09%)

Buy

$134

$57.96 (76.22%)

$132

9 months 7 days ago
(13-Nov-2024)

5/7 (71.43%)

$43.66 (48.33%)

159

Buy

$125

$48.96 (64.39%)

$100

10 months 16 days ago
(04-Oct-2024)

6/7 (85.71%)

$20.07 (19.13%)

58

Buy

$115

$38.96 (51.24%)

$99

11 months 4 days ago
(16-Sep-2024)

4/5 (80%)

$2.83 (2.52%)

77

Buy

$135

$58.96 (77.54%)

$115

11 months 4 days ago
(16-Sep-2024)

1/3 (33.33%)

$22.83 (20.35%)

64

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NUVL (Nuvalent) average time for price targets to be met?

On average it took 129.67 days on average for the stock forecasts to be realized with a an average price target met ratio 61.75

Which analyst has the current highest performing score on NUVL (Nuvalent) with a proven track record?

ETZER DAROUT

Which analyst has the current lower performing score on NUVL (Nuvalent) with a proven track record?

SWAYAMPAKULA RAMAKANTH

Which analyst has the most public recommendations on NUVL (Nuvalent)?

Etzer Darout works at BMO and has 12 price targets and 8 ratings on NUVL

Which analyst is the currently most bullish on NUVL (Nuvalent)?

Bradley Canino with highest potential upside - $58.96

Which analyst is the currently most reserved on NUVL (Nuvalent)?

Christopher Raymond with lowest potential downside - -$35.93

Nuvalent in the News

Nuvalent Inc-A (NASDAQ:NUVL) Reports Q2 2025 Earnings Miss with Focus on Oncology Pipeline Progress

Nuvalent Inc-A (NASDAQ:NUVL [https://www.chartmill.com/stock/quote/NUVL]) reported its second-quarter 2025 financial results, with earnings per share (EPS) of -$1.31, slightly missing analyst estimates of -$1.26. Revenue for the quarter came in at $0, aligning with expectations, as the clinical-stage biopharmaceutical company has yet to commercialize any products. The market reaction has been cautiously optimistic, with pre-market trading...

Nuvalent initiates rolling NDA submission for ROS1-positive NSCLC drug

CAMBRIDGE, Mass. – Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company with a market capitalization of $5.5 billion, has initiated a rolling New Drug Application (NDA) submission for zidesamtinib, its ROS1-selective inhibitor for previously treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC), the company announced Thursday. The biopharmaceutical firm aims to complete the submission...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?